Headlines

Amgen (AMGN) announces positive phase 3 DeLLphi-305 study, which met its primary endpoint when IMDELLTRA in combination with AstraZeneca's (AZN LN) Imfinzi

Newsquawk Staff ·

Amgen (AMGN) announces positive phase 3 DeLLphi-305 study, which met its primary endpoint when IMDELLTRA in combination with AstraZeneca's (AZN LN) Imfinzi.

Related headlines